Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DRR001
MIFTS: 55

Diarrhea

Categories: Gastrointestinal diseases, Genetic diseases, Infectious diseases, Nephrological diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Diarrhea

About this section

MalaCards integrated aliases for Diarrhea:

Name: Diarrhea 12 29 6 42 15 39
Diarrhoea 12 15
Diarrhea of Presumed Infectious Origin 12

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Infectious diseases
Anatomical: Gastrointestinal diseases Nephrological diseases Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:13250
ICD9CM 34 009.2
MeSH 44 D004403
SNOMED-CT 67 154268000
UMLS 71 C0013369
Sources

Summaries for Diarrhea

About this section
MedlinePlus : 42 What is diarrhea? Diarrhea is loose, watery stools (bowel movements). You have diarrhea if you have loose stools three or more times in one day. Acute diarrhea is diarrhea that lasts a short time. It is a common problem. It usually lasts about one or two days, but it may last longer. Then it goes away on its own. Diarrhea lasting more than a few days may be a sign of a more serious problem. Chronic diarrhea -- diarrhea that lasts at least four weeks -- can be a symptom of a chronic disease. Chronic diarrhea symptoms may be continual, or they may come and go. What causes diarrhea? The most common causes of diarrhea include Bacteria from contaminated food or water Viruses such as the flu, norovirus, or rotavirus . Rotavirus is the most common cause of acute diarrhea in children. Parasites, which are tiny organisms found in contaminated food or water Medicines such as antibiotics, cancer drugs, and antacids that contain magnesium Food intolerances and sensitivities, which are problems digesting certain ingredients or foods. An example is lactose intolerance. Diseases that affect the stomach, small intestine, or colon, such as Crohn's disease Problems with how the colon functions, such as irritable bowel syndrome Some people also get diarrhea after stomach surgery, because sometimes the surgeries can cause food to move through your digestive system more quickly. Sometimes no cause can be found. If your diarrhea goes away within a few days, finding the cause is usually not necessary. Who is at risk for diarrhea? People of all ages can get diarrhea. On average, adults In the United States have acute diarrhea once a year. Young children have it an average of twice a year. People who visit developing countries are at risk for traveler's diarrhea. It is caused by consuming contaminated food or water. What other symptoms might I have with diarrhea? Other possible symptoms of diarrhea include Cramps or pain in the abdomen An urgent need to use the bathroom Loss of bowel control If a virus or bacteria is the cause of your diarrhea, you may also have a fever, chills, and bloody stools. Diarrhea can cause dehydration, which means that your body does not have enough fluid to work properly. Dehydration can be serious, especially for children, older adults, and people with weakened immune systems. When do I need to see a health care provider for diarrhea? Although it is usually not harmful, diarrhea can become dangerous or signal a more serious problem. Contact your health care provider if you have Signs of dehydration Diarrhea for more than 2 days, if you are an adult. For children, contact the provider if it lasts more than 24 hours. Severe pain in your abdomen or rectum (for adults) A fever of 102 degrees or higher Stools containing blood or pus Stools that are black and tarry If children have diarrhea, parents or caregivers should not hesitate to call a health care provider. Diarrhea can be especially dangerous in newborns and infants. How is the cause of diarrhea diagnosed? To find the cause of diarrhea, your health care provider may Do a physical exam Ask about any medicines you are taking Test your stool or blood to look for bacteria, parasites, or other signs of disease or infection Ask you to stop eating certain foods to see whether your diarrhea goes away If you have chronic diarrhea, your health care provider may perform other tests to look for signs of disease. What are the treatments for diarrhea? Diarrhea is treated by replacing lost fluids and electrolytes to prevent dehydration. Depending on the cause of the problem, you may need medicines to stop the diarrhea or treat an infection. Adults with diarrhea should drink water, fruit juices, sports drinks, sodas without caffeine, and salty broths. As your symptoms improve, you can eat soft, bland food. Children with diarrhea should be given oral rehydration solutions to replace lost fluids and electrolytes. Can diarrhea be prevented? Two types of diarrhea can be prevented - rotavirus diarrhea and traveler's diarrhea. There are vaccines for rotavirus. They are given to babies in two or three doses. You can help prevent traveler's diarrhea by being careful about what you eat and drink when you are in developing countries: Use only bottled or purified water for drinking, making ice cubes, and brushing your teeth If you do use tap water, boil it or use iodine tablets Make sure that the cooked food you eat is fully cooked and served hot Avoid unwashed or unpeeled raw fruits and vegetables NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diarrhea, also known as diarrhoea, is related to diarrhea 2, with microvillus atrophy and diarrhea 5, with tufting enteropathy, congenital. An important gene associated with Diarrhea is WNT2B (Wnt Family Member 2B), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Digestion of dietary carbohydrate. The drugs Acetylcholine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include breast, colon and kidney, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Disease Ontology : 12 A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea.

Wikipedia : 74 Diarrhea, also spelled diarrhoea, is the condition of having at least three loose, liquid, or watery... more...

Sources

Related Diseases for Diarrhea

About this section

Diseases in the Diarrhea family:

Diarrhea 6 Diarrhea 9
Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity Inflammatory Diarrhea
Acute Diarrhea Congenital Diarrhea

Diseases related to Diarrhea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1377)
# Related Disease Score Top Affiliating Genes
1 diarrhea 2, with microvillus atrophy 33.3 TTC37 SLC9A3 SLC26A3 MYO5B
2 diarrhea 5, with tufting enteropathy, congenital 33.3 TTC37 SPINT2 SLC9A3 SLC26A3 NEUROG3 MYO5B
3 diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies 33.2 SPINT2 SLC9A3 GUCY2C
4 diarrhea 1, secretory chloride, congenital 33.2 SLC9A3 SLC26A3
5 diarrhea 4, malabsorptive, congenital 33.1 TTC37 NEUROG3 MYO5B
6 acute diarrhea 33.0 SLC9A3 MME
7 diarrhea 8, secretory sodium, congenital 33.0 SLC9A3 MYO5B
8 secretory diarrhea 32.9 SST SPINT2 SLC9A3 SLC26A3 MYO5B GUCY2C
9 osmotic diarrhea 32.9 WNT2B SLC9A3 SLC26A3 MGAM
10 congenital diarrhea 32.8 TTC37 SPINT2 SLC9A3 SLC26A3 NEUROG3 MYO5B
11 inflammatory diarrhea 32.7 SLC9A3 SLC26A3
12 short bowel syndrome 32.3 SST SLC9A3 CCK
13 bile acid malabsorption, primary 32.1 SST CCK
14 sucrase-isomaltase deficiency, congenital 32.0 SI MGAM
15 constipation 31.9 SST GUCY2C CYP3A4 CCK
16 serotonin syndrome 31.6 SST CYP3A4
17 ileus 31.1 SST SLC9A3 GUCY2C CCK
18 dumping syndrome 30.5 SST CCK
19 biliary dyskinesia 30.4 SST CCK
20 nutritional deficiency disease 30.4 SI MGAM CCK
21 nasopharyngitis 30.4 SI MGAM CYP3A4
22 gastroparesis 30.3 SST CYP3A4 CCK
23 meconium ileus 30.3 SLC9A3 GUCY2C
24 volvulus of midgut 30.3 SST GUCY2C
25 spermatocele 30.3 SLC9A3 SLC26A3
26 mucopolysaccharidosis-plus syndrome 30.3 SI SGSH MGAM
27 cerebral lymphoma 30.2 SST MME
28 postgastrectomy syndrome 30.2 SST SI MGAM
29 pneumatosis cystoides intestinalis 30.2 SI MGAM
30 scheie syndrome 30.1 SI SGSH MGAM
31 proprotein convertase 1/3 deficiency 30.1 NEUROG3 MYO5B
32 cholecystolithiasis 30.1 SST CCK
33 trichohepatoenteric syndrome 1 11.7
34 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.6
35 congenital chloride diarrhea 11.6
36 dysentery 11.5
37 diarrhea 6 11.5
38 diarrhea 11, malabsorptive, congenital 11.4
39 diarrhea 9 11.4
40 diarrhea 10, protein-losing enteropathy type 11.4
41 chronic diarrhea due to guanylate cyclase 2c overactivity 11.4
42 congenital diarrhea 7 with exudative enteropathy 11.3
43 hemolytic uremic syndrome, atypical 1 11.3
44 cholera 11.3
45 gastroenteritis 11.3
46 irritable bowel syndrome 11.3
47 satoyoshi syndrome 11.3
48 pancreatic cholera 11.3
49 vipoma 11.2
50 diarrhea 7, protein-losing enteropathy type 11.2

Graphical network of the top 20 diseases related to Diarrhea:



Diseases related to Diarrhea
Sources

Symptoms & Phenotypes for Diarrhea

About this section

MGI Mouse Phenotypes related to Diarrhea:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.85 DGAT1 EPCAM FOXP3 GUCY2C MYO5B NEUROG3
2 homeostasis/metabolism MP:0005376 9.77 CCK DGAT1 EPCAM FOXP3 GUCY2C MGAM
3 no phenotypic analysis MP:0003012 9.17 CCK EPCAM FOXP3 NEUROG3 NMNAT1 SST
Sources

Drugs & Therapeutics for Diarrhea

About this section

Drugs for Diarrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 416)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Donepezil Approved Phase 4 120014-06-4 3152
3
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
4
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
5
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
6
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
7
Turmeric Approved, Experimental, Investigational Phase 4
8
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
9
Copper Approved, Investigational Phase 4 7440-50-8 27099
10
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
11
Iodine Approved, Investigational Phase 4 7553-56-2 807
12
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
13
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
14
Tocopherol Approved, Investigational Phase 4 1406-66-2
15
Pemetrexed Approved, Investigational Phase 4 150399-23-8, 137281-23-3 446556 60843
16
Insulin aspart Approved Phase 4 116094-23-6 16132418
17
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
18
Simethicone Approved Phase 4 8050-81-5
19
Sodium citrate Approved, Investigational Phase 4 68-04-2
20
Ferrous fumarate Approved Phase 4 141-01-5
21
Sulfamethoxazole Approved Phase 4 723-46-6 5329
22
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
23
Metformin Approved Phase 4 657-24-9 14219 4091
24
Fidaxomicin Approved Phase 4 873857-62-6
25
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
26
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
27
Azithromycin Approved Phase 4 83905-01-5 55185 447043
28
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
29
Lactulose Approved Phase 4 4618-18-2 11333
30
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
31
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
32
Teicoplanin Approved, Investigational Phase 4 61036-62-2
33
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
34
Mycophenolic acid Approved Phase 4 24280-93-1 446541
35
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
36
Metronidazole Approved Phase 4 443-48-1 4173
37
Choline Approved, Nutraceutical Phase 4 62-49-7 305
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
39
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
41
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
42
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
43
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
44
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
45
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
46
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
47
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
48
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
50
Ramosetron Investigational Phase 4 132036-88-5

Interventional clinical trials:

(show top 50) (show all 860)
# Name Status NCT ID Phase Drugs
1 Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome Unknown status NCT03557788 Phase 4 Rifaximin Oral Tablet
2 Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial Unknown status NCT02765217 Phase 4 Lactobacillus reuteri DSM 17938;Placebo;Amoxicillin-Clavulanic Acid
3 Prophylaxis of Gastrointestinal Infections in Newborn and Infants With a Suspension Containing the Probiotic Escherichia Coli Strain Nissle Unknown status NCT01469273 Phase 4 Mutaflor® Suspension
4 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
5 The Impact of Lactobacillus Preparation on the Incidence of Diarrhea in Intensive Care Unit-admitted Patients : Randomized Controlled Trial Unknown status NCT01792739 Phase 4 Lactobacillus casei variety rhamnosus granules;Placebo
6 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
7 Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
8 Bacillus Particles Prevent More Children's Antibiotic-associated Diarrhea (AAD), Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT02993419 Phase 4 Bacillus licheniformis Intervention
9 Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes Unknown status NCT02949882 Phase 4
10 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
11 Non-specific Effects of Rabies Vaccine on the Incidence of Common Infectious Disease Episodes: a Randomized Controlled Trial Unknown status NCT03656198 Phase 4 Sterile Water Injection
12 Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D). Completed NCT01316718 Phase 4 Mesalazine;Placebo
13 Rapid Diagnostics and Probiotic Therapy for Paediatric Acute Gastroenteritis - a Randomized, Factorial, Controlled, Placebo-controlled, Pilot Trial Completed NCT02025452 Phase 4
14 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01225237 Phase 4 Ramosetron;Placebo
15 Study Title: Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
16 Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study Completed NCT00228254 Phase 4 Zinc (12.5 mg/day);vitamin A 10,000 IU per week
17 STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea Completed NCT00050635 Phase 4 Sandostatin LAR Depot
18 Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis: Randomized, Double-Blind Controlled Trial Completed NCT01467570 Phase 4
19 Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis: A Double Blind Randomized, Placebo- Controlled Trial Completed NCT01657032 Phase 4
20 Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes Completed NCT00470158 Phase 4
21 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
22 Efficacy of Diosmectite (Smecta®) in the Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomised, Double Blind, Placebo Controlled, Parallel Groups Study. Completed NCT00276328 Phase 4 Diosmectite (Smecta®)
23 Introduction of New Hypo-osmolar ORS Into Routine Use in the Management of Diarrhoeal Disease: a Phase IV Clinical Surveillance. Completed NCT00244777 Phase 4 Hypo-osmolar ORS
24 Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomized, Double Blind Placebo Controlled, Parallel, Groups Study Completed NCT02704091 Phase 4 Smecta;Smecta placebo
25 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D): Identifying the "Responder" Completed NCT00745004 Phase 4 Ondansetron;Placebo
26 Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea Completed NCT03833999 Phase 4 Ondansetron 8mg;Lactulose;Placebo oral capsule
27 A Randomised Placebo Controlled Trial of "Follow on" Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4 Rifaximin;Placebo
28 Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea Completed NCT03059537 Phase 4 Oral chenodeoxycholic acid stimulation
29 A Community Based Intervention and Evaluation of the Impact of Social Marketing of a Diarrhea Management Pack(Comprising of Low Osmolality ORS, Zinc Tablets, Water Purification Tablets and Pictorial Chart) on Childhood Diarrhea. Completed NCT00942812 Phase 4
30 The Effect of a Probiotic and/or Prebiotic on the Duration of Diarrhea and Length of Hospital Stay in Children With Acute Diarrhea: Prospective, Double Blind, Randomized Controlled Trial Completed NCT01927094 Phase 4
31 Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Efficacy and Safety Completed NCT00447161 Phase 4 Bacillus Clausii Multi ATB Resist;Placebo
32 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
33 Comparison of Efficacy and Safety of Prandilin and NovoRapid Evaluated by Continuous Glucose Monitoring System in Newly Diagnosed Type 2 Diabetes Completed NCT03226210 Phase 4 aspart insulin or lipro insulin
34 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
35 The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19 Completed NCT04479202 Phase 4 Berberine;Montmorrillonite
36 Oral Administration of Tannins and Flavonoids in Children With Acute Diarrhea : A Pilot, Randomized, Control-case Study Completed NCT03356327 Phase 4 Actitan F;Standard Oral Rehydration
37 A Post -Marketing Drug Evaluation(Phase IV Clinical Trial) to Study the Safety and Efficacy of Heweizhixie Capsule in Patients With Diarrhea Completed NCT02607176 Phase 4 Heweizhixie capsule
38 Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial Completed NCT02871908 Phase 4 Lactobacillus reuteri DSM 17938;Placebo
39 A Placebo-Controlled, Double-Blind, Randomized Pilot Study to Evaluate the Appropriateness of Multiple Endpoints in Measuring the Onset of Clinical Efficacy of Loperamide-Simethicone Caplets in the Treatment of Acute Non-specific Diarrhea Completed NCT00685607 Phase 4 loperamide-simethicone;matching placebo
40 An Open-label, Pilot Study to Compare the Safety and Immunogenicity of an Alternate Dosing Schedule (2-5 Weeks, 2 Months, and 4 Months) for Pentavalent Rotavirus Vaccine (RotaTeq) to the Standard Recommended Schedule (2, 4, and 6 Months) Completed NCT01960725 Phase 4
41 Postmarketing Study of Probiotics Medication in Childhood Diarrhea Completed NCT00463190 Phase 4 Biothree
42 Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea Completed NCT00292344 Phase 4 Rifaximin and loperamide
43 Effect of Zinc Sulphate and Zinc Amino Acid Chelate in Prevention Acute Diarrhea and Acute Respiratory Infection, Medellín 2012 Completed NCT01791608 Phase 4
44 Lactobacillus Casei e Bifidobacterium Breve as Probiotics at the Treatment of Antibiotic Associated Diarrhea: a Randomized Double Blind Study Completed NCT00700557 Phase 4
45 Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome Completed NCT02111603 Phase 4 Colesevelam
46 3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM) Completed NCT03441581 Phase 4 Eluxadoline
47 Loperamide Plus Azithromycin More Effectively Treats Travelers' Diarrhea In Mexico Than Azithromycin Alone Completed NCT00359970 Phase 4 Azithromycin 500 mg;Azithromycin 1000 mg;Loperamide
48 Phase 4 Study of Probiotics on Intestinal Bacterial Population and Immune Modulation Completed NCT00763399 Phase 4
49 Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children: A Randomized Double-blind Trial Completed NCT01564290 Phase 4 Placebo probiotic
50 Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Under Six Months. Completed NCT01571856 Phase 4 Zinc Sulfate

Search NIH Clinical Center for Diarrhea

Sources

Genetic Tests for Diarrhea

About this section

Genetic tests related to Diarrhea:

# Genetic test Affiliating Genes
1 Diarrhea 29
Sources

Anatomical Context for Diarrhea

About this section

MalaCards organs/tissues related to Diarrhea:

40
Breast, Colon, Kidney, Small Intestine, Thyroid, Skin, Prostate
Sources

Publications for Diarrhea

About this section

Articles related to Diarrhea:

(show top 50) (show all 57204)
# Title Authors PMID Year
1
Therapy of diarrhea in COVID-19 with external treatment of traditional Chinese medicine: A protocol for systematic review and meta-analysis. 61 42
33429783 2021
2
Electronic decision support and diarrhoeal disease guideline adherence (mHDM): a cluster randomised controlled trial. 42 61
33328057 2020
3
Study on the clinical mechanism of Tong-Xie-An-Chang Decoction in the treatment of diarrheal irritable bowel syndrome based on single-cell sequencing technology. 42
33350782 2020
4
Antimicrobial resistance and gene regulation in Enteroaggregative Escherichia coli from Egyptian children with diarrhoea: Similarities and differences. 61
33372849 2021
5
Comprehensive analysis of lncRNA expression profiles in cytopathic biotype BVDV-infected MDBK cells provides an insight into biological contexts of host-BVDV interactions. 61
33258421 2021
6
Comparative effectiveness of lactulose and sennosides for the prevention of peritoneal dialysis-related peritonitis: an open-label, randomized, active-controlled trial. 61
33596746 2021
7
Sauropus brevipes ethanol extract negatively regulates inflammatory responses in vivo and in vitro by targeting Src, Syk and IRAK1. 61
33439064 2021
8
Dynamic Dissection of Dynein and Kinesin-1 Cooperatively Mediated Intercellular Transport of Porcine Epidemic Diarrhea Coronavirus along Microtubule Using Single Virus Tracking. 61
33538234 2021
9
Infection of polarized bovine respiratory epithelial cells by bovine viral diarrhea virus (BVDV). 61
33300445 2021
10
Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells. 61
33417512 2021
11
Prospect of microbial food borne diseases in Pakistan: a review. 61
33605364 2021
12
Pharmacologycal activity of peperina (Minthostachys verticillata) on gastrointestinal tract. 61
33352243 2021
13
Mechanisms of antidiarrhoeal activity of methanol leaf extract of Combretum hypopilinum diels (combretaceae): Involvement of opioidergic and (α1 and β)-adrenergic pathways. 61
33359856 2021
14
Correlation analysis between extracts and endogenous metabolites to characterise the influence of salt-processing on compatibility mechanism of 'Psoraleae Fructus & Foeniculi Fructus'. 61
33421603 2021
15
Effects of Zinc Oxide/Zeolite on Intestinal Morphology, Intestinal Microflora, and Diarrhea Rates in Weaned Piglets. 61
32607765 2021
16
Regulatory effect and mechanism of APN gene on porcine epidemic diarrhea virus resistance. 61
33482281 2021
17
Traditional uses, phytochemistry, pharmacology, and toxicology of Coreopsis tinctoria Nutt.: A review. 61
33309917 2021
18
Serum 7-alfa-hydroxy-4-cholesten-3-one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease. 61
33177381 2021
19
Quantitative Analysis of Intramucosal Mast Cells in Irritable Bowel Syndrome: A Comparison With Inflammatory Bowel Disease in Remission. 61
32649443 2021
20
Impact of concurrent treatment with omeprazole on phenylbutazone-induced equine gastric ulcer syndrome (EGUS). 61
32697849 2021
21
Development of Crohn's Disease in a Child With SLC26A3-related Congenital Chloride Diarrhea: Report of the First Case in East Asia and a Novel Missense Variant. 61
33063691 2021
22
Chemotherapy-induced diarrhoea in dogs and its management with smectite: Results of a monocentric open-label randomized clinical trial. 61
32562450 2021
23
Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children. 61
33028102 2021
24
Liver Steatosis and Diarrhea After Liver Transplantation for Progressive Familial Intrahepatic Cholestasis Type 1: Can Biliary Diversion Solve These Problems? 61
33230072 2021
25
The perception gap of chemotherapy-induced adverse events between doctors and cancer patients: an observational study in China. 61
32728801 2021
26
Ethnopharmacological basis for folkloric claims of Anagallis arvensis Linn. (Scarlet Pimpernel) as prokinetic, spasmolytic and hypotensive in province of Punjab, Pakistan. 61
33246113 2021
27
Temporal trends in bulk tank milk antibody ELISA and PCR test results for bovine viral diarrhoea in New Zealand pastoral dairy herds. 61
32814505 2021
28
Replicative capacity of four porcine enteric coronaviruses in LLC-PK1 cells. 61
33492525 2021
29
Open-label study to evaluate the treatment continuation rate after a dose reduction of lubiprostone due to onset of adverse events. 61
33206011 2021
30
[Epidemiological specificities of COVID-19 in Africa: Current or future public health concern?] 61
33091399 2021
31
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. 61
33275318 2021
32
Observation of Giardia sp. in the termite gut of Heterotermes tenuis. 61
33511472 2021
33
Alcohol use disorder and the gut. 61
32511812 2021
34
Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand. 61
33531197 2021
35
Complete clinical response of a neglected cutaneous melanoma with combined radiotherapy and immunotherapy: A case report. 61
32909385 2021
36
The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. 61
32676853 2021
37
Investigation of ethnomedicinal use of Commiphora leptophloeos (Mart.) J. B. Gillett (Burseraceae) in treatment of diarrhea. 61
33166628 2021
38
Enhanced Protection Against Diarrhea Among Breastfed Infants of Nonsecretor Mothers. 61
33315747 2021
39
Effects of fermented ginseng on the gut microbiota and immunity of rats with antibiotic-associated diarrhea. 61
33217518 2021
40
Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. 61
33068689 2021
41
Prevalence and phylogenetic analysis of spike gene of porcine epidemic diarrhea virus in Henan province, China in 2015-2019. 61
33412288 2021
42
TRAPγ-CDG shows asymmetric glycosylation and an effect on processing of proteins required in higher organisms. 61
32332102 2021
43
Effect of ambient temperatures on category C notifiable infectious diarrhea in China: An analysis of national surveillance data. 61
33198999 2021
44
Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. 61
33585034 2021
45
Bougainvillea glabra (choisy): A comprehensive review on botany, traditional uses, phytochemistry, pharmacology and toxicity. 61
32956758 2021
46
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry. 61
33538994 2021
47
The overlap between irritable bowel syndrome and organic gastrointestinal diseases. 61
33189181 2021
48
Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis. 61
32220613 2021
49
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. 61
32907501 2021
50
Transient bilateral chorea secondary to digoxin toxicity in a female with acute kidney injury: a case report. 61
33569535 2021
Sources

Variations for Diarrhea

About this section

ClinVar genetic disease variations for Diarrhea:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 WNT2B NM_024494.3(WNT2B):c.205C>T (p.Arg69Ter) SNV Pathogenic 545432 rs370244148 1:113057518-113057518 1:112514896-112514896
2 SGSH NM_000199.5(SGSH):c.1272_1282del (p.Tyr424_Arg428delinsTer) Deletion Pathogenic 287037 rs752914124 17:78184478-78184488 17:80210679-80210689
3 SGSH NM_000199.5(SGSH):c.892T>C (p.Ser298Pro) SNV Pathogenic 30459 rs138504221 17:78185927-78185927 17:80212128-80212128
4 NMNAT1 NM_022787.4(NMNAT1):c.769G>A (p.Glu257Lys) SNV Likely pathogenic 37134 rs150726175 1:10042688-10042688 1:9982630-9982630
5 RASL12 NM_178859.4(SLC51B):c.84del (p.Arg29fs) Deletion Likely pathogenic 804474 rs1595900104 15:65342421-65342421 15:65050083-65050083
6 OCA2 NM_000275.3(OCA2):c.2020C>G (p.Leu674Val) SNV Uncertain significance 194918 rs371412500 15:28171332-28171332 15:27926186-27926186
7 UNC45A NM_018671.5(UNC45A):c.710T>C (p.Leu237Pro) SNV Uncertain significance 978046 15:91485689-91485689 15:90942459-90942459
8 UNC45A NM_018671.5(UNC45A):c.1339_1340delinsCT (p.Ala447Leu) Indel Uncertain significance 978047 15:91489983-91489984 15:90946753-90946754
Sources

Expression for Diarrhea

About this section
Search GEO for disease gene expression data for Diarrhea.
Sources

Pathways for Diarrhea

About this section

Pathways related to Diarrhea according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.26 WNT2B NEUROG3 EPCAM
2
Digestion of dietary carbohydrate 65
9.58 SI MGAM
Sources

GO Terms for Diarrhea

About this section

Cellular components related to Diarrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 brush border GO:0005903 9.13 SLC9A3 SI MME
2 apical plasma membrane GO:0016324 9.02 SLC9A3 SLC26A3 SI MGAM EPCAM

Biological processes related to Diarrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polysaccharide digestion GO:0044245 8.96 SI MGAM
2 digestion GO:0007586 8.8 SST GUCY2C CCK

Molecular functions related to Diarrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 alpha-1,4-glucosidase activity GO:0004558 8.62 SI MGAM
Sources

Sources for Diarrhea

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....